251 related articles for article (PubMed ID: 20408960)
1. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
Hirose T; Ishizawa K; Shimada S
Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
[TBL] [Abstract][Full Text] [Related]
2. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
4. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
[TBL] [Abstract][Full Text] [Related]
6. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
7. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
8. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections.
Burger PC; Minn AY; Smith JS; Borell TJ; Jedlicka AE; Huntley BK; Goldthwaite PT; Jenkins RB; Feuerstein BG
Mod Pathol; 2001 Sep; 14(9):842-53. PubMed ID: 11557779
[TBL] [Abstract][Full Text] [Related]
9. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
11. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; El Hallani S; Sanson M; Crinière E; Rodero M; Carpentier C; Paris S; Laigle-Donadey F; Ducray F; Hoang-Xuan K; Delattre JY
Cancer Genet Cytogenet; 2007 Sep; 177(2):103-7. PubMed ID: 17854663
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.
Birner P; Preusser M; Gelpi E; Berger J; Gatterbauer B; Ambros IM; Ambros PF; Acker T; Plate KH; Harris AL; Hainfellner JA
Clin Cancer Res; 2004 Oct; 10(19):6567-71. PubMed ID: 15475445
[TBL] [Abstract][Full Text] [Related]
13. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
Jha P; Agarwal S; Pathak P; Srivastava A; Suri V; Sharma MC; Chosdol K; Srivastava T; Gupta D; Gupta A; Suri A; Sarkar C
Cancer Genet Cytogenet; 2010 Apr; 198(2):126-34. PubMed ID: 20362227
[TBL] [Abstract][Full Text] [Related]
14. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ
Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114
[TBL] [Abstract][Full Text] [Related]
15. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
17. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
18. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
20. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors.
Fujisawa H; Marukawa K; Hasegawa M; Tohma Y; Hayashi Y; Uchiyama N; Tachibana O; Yamashita J
J Neurosurg; 2002 Dec; 97(6):1350-5. PubMed ID: 12507133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]